£16.1M
Systemiq Ventures led the Series A round to support team expansion and product development.
"At Basecamp, we know the answers to our greatest challenges can be uncovered in our environment,"
Filter & sort
The latest funding rounds from the UK tech ecosystem. Updated 2 November 2026.
Announcements
1,179
Total raised
£24.7B
disclosed amounts
This month
£9.0M
raised so far
Systemiq Ventures led the Series A round to support team expansion and product development.
"At Basecamp, we know the answers to our greatest challenges can be uncovered in our environment,"
Spark Capital led the Series A round, which will fund US expansion and team growth.
"Steven, Hussam and the 9fin team are updating an industry that desperately needs it. They’ve made so much progress out of their London office, we’re excited to see them take on the US and continue growing with new customers."
The Stevenage enterprise raised the capital from Longwall Ventures and a syndicate of backers to fund trials and product development.
"Advanced therapy manufacturing is hindered by out of date, inadequate manufacturing technologies,"
The investment was co-led by Novum Capital Partners and Fifth Wall to support international expansion and product development.
"From the first meeting, we were completely bought into Vivi and Karolina’s vision. AltoVita is one of the most capital efficient operations that I’ve seen in many years and the growth AltoVita has achieved is rare, particularly within the current market challenges. The company brings a truly unique offering to the corporate travel market and we couldn’t be happier to see the progress that the team has made over the past year. Our recent investment will give AltoVita the firepower to scale its vision into new markets, and continue to develop its seamless solution for the fragmented corporate accommodation sector."

The financing round was backed by Maven Capital Partners, YFM Equity Partners, Triple Point Ventures, and regional funds to support US growth.
"Drug discovery is so exciting right now, as there are just so many incredible companies working on remarkable new therapeutics. Equally, we are at a time where there is a stupendous amount of untapped evidence, like cause-and-effect, sat dark and subsequently unused by these same companies. Our mission at Biorelate is to capture this untapped data and help them make sense of it. With this improved understanding we are empowering these companies to make better decisions and speed up the drug discovery process."